anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The main objective of our study was to assess the clinical implications of concomitant intraoperative removal of maxillary third molars (M3M) with the Le Fort I osteotomy 'twist' technique (LF1twist). A prospective comparative study was carried out regarding the necessity of bone trimming around the pedicle, intra- and postoperative complications, surgery time, and the level of pterygomaxillary junction (PMJ) separation following LF1twist with concomitant intraoperative removal of M3M (test group) versus LF1twist alone (control group). Outcome parameters were assessed from clinical and radiographic measurements. In total, 100 surgery sites were included (50 in each group). The mean surgery time was 53.4 ± 7.8 min, with nonsignificant differences between groups. The frequency of intraoperative complications was negligible, with no significant differences between groups - though all bleeding events (n = 4) occurred when M3M was not removed concomitantly. No postoperative complications were recorded. Percentages of disarticulations occurring at the PMJ were similar in both groups. In conclusion, the results demonstrate that removal of M3M in conjunction with LF1twist does not imply additional surgery time, or differences regarding the level of PMJ separation or perioperative complications. Furthermore, the concomitant procedure reduces the amount of maxillary and palatal bone in the disjunction area, which facilitates down-fracture and field clearing for maxillary repositioning.
The presentation and course of late-onset Pompe disease is much less foreseeable than the classic infantile form. Some patients experience a rapid worsening in skeletal muscle function leading to loss of ambulation and respiratory failure, while others progress less rapidly. So there is a more inconstant response to treatment in skeletal muscle and lung function in the long-term. Therefore, an unmet clinical need is the collection and analysis of long-term data of rhGAA enzyme replacement therapy (ERT) in late-onset Pompe disease patient aged 8 years and older. The principal goal of our investigator driven study is to gain conclusive insight in long-term outcome data beyond 36 months up to 10 years of ERT treatment. In addition we will collect biological samples from all patients for a future biomarker study including gene modifier search by genome and RNA seq (not part of this proposal). This study may provide clinicians and researchers with a better understanding of late-onset Pompe disease under long-term treatment, to the benefit of all patients affected with late-onset Pompe disease, as well as, individuals and families with related diseases.
The invention provides a skin tinea eliminating cream, which belongs to the technology field of medicament, and provides an externally applied agent for treating superficial fungal diseases, such as tinea corporis, tinea cruris, tinea manus and tinea pedis and other fungal infections. The medicament is mainly composed of laurinol, camphor, ethyl p hydroxybenzoate, azithromycin, propylene glycol and other ten components. The product is mainly used for promoting recovery of damaged skin and tissue. The product is free of irritation after smearing during usage process. By using the treatment method, the cure rate is increased to 95% or above. The product can obviously shorten the treatment time. The ointment containing antibiotic and camphor component fills a blank in the medicament field.
FIELD: veterinary science. SUBSTANCE: an agent has bioavailable iron and amino acid component. Components taken at the definite ratio provide retention of physiologically normal blood composition in animal. Composition is produced as a free-friable powder by spraying-drying method. Composition has an internal core covered by continuous layer with amino acid component. Iron is assimilated good from the proposed composition that prevents animal death. Iron-containing composition can be used for treatment of suckling animals with anemia. EFFECT: enhanced effectiveness of composition. 57 cl, 5 dwg, 2 tbl, 3 ex
Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) programed to provide placebo therapy. Each treatment session consisting of 30 minutes of sham therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
Dietary intervention studies thus far have failed to be replicable or causal. The results, therefore, have failed to provide clinicians and the general public with consistent and useful information on which to base reliable food-related health decisions. This is particularly relevant regarding plastic-derived chemicals (PDCs), such as Bisphenol A, now that the federal CLARITY-BPA program has failed to achieve scientific consensus. Investigators propose a novel human dietary protocol that is both replicable and causal, based upon BPA's demonstrated inflammatory effects in humans. This first-of-a-kind dietary intervention study explores a potential causal relationship between human serum levels of BPA and High-Sensitivity C-Reactive Protein (hsCRP), a proven clinical indicator of inflammation. Investigators used the equivalent of a USDA-defined "typical diet" followed by a PDC-reduced diet to compare blood levels of hsCRP. This proof-of-concept investigation is the first to use an easily accessible, medically-accepted clinical laboratory test to directly measure human health effects of PDC reduction. Unexpected new complications discovered during the investigation indicate that these results may yet be inconclusive for direct causal relationship. However, the novel lessons and techniques developed as a result of those discoveries offer further specific and improved methods and best practices that can enable future dietary interventions to produce replicable, causal results.
PURPOSE:To obtain the titled tissual plasminogen activator, useful as a thrombolytic agent, and having high safety without side effects, by adding albumin to a purifying or powdering step of a tissual plasminogen activator. CONSTITUTION:In any one of a purifying or powdering step of a tissual plasminogen activator (hereinafter abbreviated to TPA), albumin is added thereto. TPA is separated and purified from human or animal cells, and the affinity chromatographic method is particularly good for the separation and purification. TPA is unstable in a high purity, but stable in a crude enzymic solution. Therefore, the addition of the albumin is found to provide the stability by the method. The amount of the albumin to be added is generally in the range of 0.001-10% (W/V) based on the crude enzymic solution. TPA is capable of bonding firmly to fibrin as opposed to the urokinase to exhibit the activity thereof in the presence of the fibrin. Thus, the TPA has the thrombolytic activity without exhibiting side effects, e.g. hemorrhage.
The study consists of three parts: a single ascending dose escalation of IT VSV-IFNβ-NIS monotherapy, a monotherapy IV regimen selection phase and an expansion phase, designed to explore the safety and efficacy of the chosen monotherapy regimen alone or in combination with avelumab in patients with metastatic colorectal cancer. Monotherapy will also be explored in patients with pheochromocytoma and NET.

Patients are required to have at least 1 measurable lesion per RECIST 1.1, and in the IT-containing arms this lesion should be amenable for a one-time IT injection of VSV-IFNβ-NIS. At least one patient per IT cohort is required to have at least 2 measurable lesions per RECIST 1.1, one for a one-time IT injection of VSV-IFNβ-NIS and one to be used as a control. Priority enrollment in the IT-containing arms will be granted to patients with 2 measurable lesions per RECIST 1.1. At least one patient per dose level should have metastatic colorectal cancer. In order to fulfil these requirements, at least 3 or 4 patients will be required per escalation dose cohort. Other tumor types of particular interest based on prior experience with VSV or oncolytic viruses include malignant melanoma and endometrial cancer. When more than one cohort is open simultaneously, slot assignment will be determined by the sponsor in consultation with the PIs.
BACKGROUND: Human papillomaviruses are common in the urogenital tract amongst women of childbearing age. A few studies indicate a possible association between human papillomavirus infections in pregnancy and adverse pregnancy outcomes whilst other studies find no such association. We aimed to investigate the association between human papillomavirus infections during pregnancy and adverse pregnancy outcomes linked to placental dysfunction, including hypertensive disorders of pregnancy, gestational diabetes mellitus and newborns small for gestational age.
MATERIALS AND METHODS: Pregnant women from the general population in Norway and Sweden were enrolled at the time of routine mid-gestational ultrasound examination. Urine samples collected at mid-gestation in 950 and at delivery in 753 participants, were analyzed for 28 human papillomavirus genotypes, including 12 high-risk genotypes. Participants completed electronic questionnaires at enrollment and medical records were reviewed for background characteristics and for the following adverse pregnancy outcomes: hypertensive disorders of pregnancy including gestational hypertension, preeclampsia, superimposed preeclampsia, eclampsia and Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome, gestational diabetes mellitus, and newborns small for gestational age. Associations between adverse pregnancy outcomes and (a) any human papillomavirus, high-risk human papillomavirus and human papillomavirus genotype 16 infection at mid-gestation, (b) multiple genotype infections at mid-gestation, and (c) persisting infections during pregnancy were assessed with univariable and multivariable logistic regression models. Missing covariates were imputed using multiple imputation.
RESULTS: At mid-gestation, 40% (377/950) of women were positive for any of the 28 genotypes, 24% (231/950) for high-risk genotypes and human papillomavirus 16 was found in 6% (59/950) of the women. Hypertensive disorders of pregnancy was observed in 9% (83/950), gestational diabetes mellitus in 4% (40/950) and newborns small for gestational age in 7% (67/950). Human papillomavirus infection with any genotype, high-risk or human papillomavirus genotype 16 at mid-gestation was not associated with adverse pregnancy outcomes. No associations were found for multiple genotype infections at mid-gestation or persisting infections.
CONCLUSION: In a general population of pregnant women, we found no evidence of human papillomavirus infections during pregnancy being associated with hypertensive disorders of pregnancy, gestational diabetes mellitus, or newborns small for gestational age.
TRIAL REGISTRATION: Trial registration The study is registered at ClincialTrials.gov; NCT02449850 on May 19th, 2015.
The invention provides an edaravone composition for injection, and relates to the technical field of medicine manufacturing. The main medicine of the composition comprises edaravone and melatonin, wherein the melatonin comprises a quick release part and a cyclodextrin-included slow release part. According to the edaravone composition for injection provided by the invention, the therapeutic effect of edaravone is improved, instability caused by oral administration of MT (Melatonin) is avoided and MT is quick to distribute and eliminate and the like, and the first pass effect of MT is reduced. The dosage of edaravone is reduced, and the side effect of edaravone is reduced. The design of dosage combining quick release and slow release is in accordance with secretion characteristic of MT, so that the problem of half-life period of MT is solved and the bioavailability of a product is improved. The melatonin combined with edaravone acted on nerve cells has the synergistic effect of preventing encephaledema, reducing the infarct volume and improving the neurological function.
FIELD: medicine. SUBSTANCE: method involves making contraception by means of preparation containing estrogen selected from 2.0-6.0-mg of 17β- estradiol and 0.015-0.02 mg of ethynyl estradion and gestagen selected from 0.05- 0.075 mg of Gestodene, 0.075-0.125 mg of Levonorgestrel, 0.06-0.15 mg of Desogestrel, 0.06-0.15 mg of 3-keto-desogestrel, 0.1-0.3 mg of Drospyrenon, 0.1-0.2 mg of Cyproterone acetate, 0.2-0.3 mg of Norgestimate and more than 0.35-0.75 mg of Noretisteron. The dosing form is administered during 23-24 days beginning from the first day of the menstrual cycle and following 4-5 days without taking pills or taking pills containing no drugs. The total administration cycle being is 28 days long. Individual dosage forms have constant amount of estrogen/gestagen the whole 23-24 days long. EFFECT: improved control of the cycle; low hormone doses. 16 cl, 2 dwg
FIELD: organic chemistry, medicine. SUBSTANCE: invention describes new compounds of the formula (I)   where R is taken from saturated alkyls, cycloalkyls, or a group of the formula (II)   where G means CH or nitrogen; m = 0-4; R,R 2  and R 3  are similar or distinct and taken from hydrogen, halide atoms, C 1 -C 5 -alkyl, cyano-, nitro-group, -CO-NH 2 , or its pharmacologically active salt. New compounds can be used for treatment of patients with central nervous system disorders. Invention describes also a method for synthesis of the above indicated compounds, a pharmaceutical composition based on compound of the formula (I) and a method of treatment of patients with central nervous system disorders using compound of the formula (I). EFFECT: improved method of synthesis, enhanced effectiveness of compounds synthesized. 10 cl, 1 tbl, 5 ex
The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
BACKGROUND: Type 1 diabetes (T1D) is a complex multi-system disease which arises from both environmental and genetic factors, resulting in the destruction of insulin-producing pancreatic beta cells. Over the past two decades, human genetic studies have provided new insight into the etiology of T1D, including an appreciation for the role of beta cells in their own demise.
SCOPE OF REVIEW: Here, we outline models supported by human genetic data for the role of beta cell dysfunction and death in T1D. We highlight the importance of strong evidence linking T1D genetic associations to bona fide candidate genes for mechanistic and therapeutic consideration. To guide rigorous interpretation of genetic associations, we describe molecular profiling approaches, genomic resources, and disease models that may be used to construct variant-to-gene links and to investigate candidate genes and their role in T1D.
MAJOR CONCLUSIONS: We profile advances in understanding the genetic causes of beta cell dysfunction and death at individual T1D risk loci. We discuss how genetic risk prediction models can be used to address disease heterogeneity. Further, we present areas where investment will be critical for the future use of genetics to address open questions in the development of new treatment and prevention strategies for T1D.
Apparatus and associated methods relate to predicting a health outcome of a patient by a machine learning model operating on a video stream of the patient. Video data, audio data, and semantic text data are extracted from a video stream of the patient. The video data are analyzed to identify a first feature set. The audio data are analyzed to identify a second feature set. The semantic text data are analyzed to identify a third feature set. Using a computer-implemented machine-learning model, a health outcome of the patient is predicted based on the first, second, and/or third features sets. The health outcome that is predicted is then reported.
A chitosan-based polymeric nitric oxide donor composition comprising a modified chitosan polymer and a nitric oxide [N<SMALLCAPS>2</SMALLCAPS>O<SMALLCAPS>2</SMALLCAPS>] dimer, wherein the nitric oxide [N<SMALLCAPS>2</SMALLCAPS>O<SMALLCAPS>2</SMALLCAPS>] dimer is bonded directly to the backbone of the modified chitosan polymer without further binding through a nucleophile residue or moiety. The chitosan-based polymeric nitric oxide donor composition is capable of site specific delivery and controlled release of nitric oxide under physiological conditions. The chitosan-based polymeric nitric oxide donor composition further provides a carrier having medically beneficial properties. A method is further included for preparing a chitosan-based polymeric nitric oxide donor composition comprising reacting a nitric oxide dimer (80-100 p.s.i.) with a modified chitosan polymer in the presence of sodium methoxide at room temperature. The chitosan-based polymeric nitric oxide composition can be incorporated into dry powder inhalers, wound dressings, implants, injectables, condoms, wound dressings and prosthesis coatings for use in a variety of medical applications in which an effective dosage of nitric oxide is indicated as a preferred method of treatment.
Thiamine-responsive megaloblastic anaemia (TRMA) is a rare autosomal recessive disorder characterised by the clinical triad of megaloblastic anaemia, sensorineural hearing loss and diabetes mellitus (DM) in young patients. We present a case of a young man with type 1 DM who presented with pancytopenia of unclear aetiology, initially attributed to a COVID-19 infection. After obtaining a bone marrow biopsy and pursuing genetic testing, two pathogenic variants of the SLC19A2 gene consistent with TRMA were discovered in this patient. Treatment with 100 mg of thiamine oral supplementation daily led to the complete resolution of his pancytopenia. It is important to consider a genetic cause of pancytopenia in a young person. Early recognition and diagnosis of TRMA can be life-altering given early treatment can reduce insulin requirements and resolve anaemia.
The study aimed to explore the pathogenesis of secondary frozen shoulder and its influence on synovium tissue and angiogenesis by constructing a rat secondary frozen shoulder model along with transforming growth factor. 40 healthy male rats aged 8 weeks were divided into Sham group (n=10, no modeling treatment), Control group (n=10, modeling treatment), Low group (n=10, modeling treatment, and 10 mL/d transforming growth factor), and High group (n=10, modeling treatment, and 20 mL/d transforming growth factor). Hematoxylin and Eosin (HE) method was used for histological detection, and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and immunohistochemical staining method were adopted to detect the expression of Matrix metalloproteinase-14 (MMP-14), mitogen-activated protein kinase (p38MAPK), and Vascular endothelial growth factor (VEGF). Compared with Sham group, the range of abduction and external rotation of rat glenohumeral joint in Control group, Low group, and High group was significantly reduced, and High group had the smallest range. Compared with the Sham group, the synovium in the Control group, the Low group, and the High group had obvious hyperplasia, and the blood vessels were significantly increased. Immunohistochemical staining and RT-PCR results showed that compared with Sham group, MMP-14, p38 MAPK, and VEGF in Control group, Low group, and High group all increased significantly, among which High group increased most. The secondary frozen shoulder is mainly manifested as synovial hyperplasia and increased blood vessels, which are related to the induction of MMP-14, p38 MAPK, and VEGF by transforming growth factor, which reveals the pathogenesis of secondary frozen shoulder to a certain extent, and lays a foundation for subsequent clinical treatment of secondary frozen shoulder.
Atrial fibrillation is one of the most common arrhythmia around the word. Prolonged atrial fibrillation may lead to structural changes in the heart such as atrial enlargement, which is an important risk factor for heart failure. Sacubitril/Valsartan is a new drug for the treatment of heart failure, previous studies have shown that it has a good effect in improving cardiac function. For patients with persistent atrial fibrillation and enlarged left atrial, the effect of reversing cardiac remodeling after catheter ablation is unclear. Some studies have described its positive effects in improving cardiac remodeling, but there is still no large-scale randomized controlled trial to further confirm. The investigators hypothesized that Sacubitril/Valsartan can reverse cardiac remodeling in patients with persistent atrial fibrillation and enlarged left atrium compared with ARB after catheter ablation.
Cannabidiol (CBD) for use in the treatment of epilepsy, wherein the epilepsy is treatment-resistant epilepsy (TRE), and wherein the epilepsy to be treated is characterised by atonic seizures, is provided. Preferably the atonic seizures to be treated are in patients diagnosed with Lennox-Gastaut syndrome, tuberous sclerosis complex, Dravet syndrome, Doose syndrome, CDKL5 and Dup15q. The CBD is preferably for use in combination with one or more concomitant anti-epileptic drugs (AED), in particular clobazam, levetiracetam, topiramate, stiripentol, phenobarbital, lacsamide, valproic acid, zonisamide, perampanel and fosphenytoin, wherein the dose of the anti-epileptic drug/s that is/are used in combination with CBD is reduced. Preferably the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD. Preferably the extract further comprises up to 1% CBDV (cannabidivarin) and less than 0.15% THC (tetrahydrocannabinol). Preferably the dose of CBD is from 5mg/kg/day to 25mg/kg/day.
In various instances, the surgical instrument can include a data storage protocol and/or at least one security feature. The surgical instrument can include a locking circuit, for example. In various instances, the surgical instrument can include sensors and/or magnets for detecting various characteristics of the surgical instrument, surgical operation, and/or surgical site. The surgical instrument can require a temporary access code for operating and/or can be selected for connection to an external display. A surgical system can include a first modular component, a second modular component, and a feedback system. The feedback system can include an engagement sensor, which can detect the engagement and/or degree of engagement of the first modular component and the second modular component.